# 📊 FINAL CLINICAL ANALYSIS REPORT

**Date:** October 29, 2025  
**Status:** ✅ **COMPLETE - NO RISK CATEGORY BIAS**

---

## EXECUTIVE SUMMARY

Complete clinical analysis of **25 APOE-genotyped glioma patients** with **HRR024685 included** and **NO risk category bias**.

### Key Changes:
- ✅ **HRR024685 (ε4/ε4) NOW INCLUDED** - The only high-risk APOE genotype in cohort
- ✅ **NO RISK CATEGORIES** - Genotypes analyzed individually without bias
- ✅ **All 25 patients** with complete HRR-CGGA mapping
- ✅ **100% clinical data coverage**

---

## COHORT COMPOSITION

### Total Patients: **25**

### APOE Genotype Distribution:
| Genotype | Count | Percentage | Notes |
|----------|-------|------------|-------|
| **ε3/ε3** | 14 | 56% | Most common (neutral genotype) |
| **ε2/ε3** | 7 | 28% | Second most common |
| **ε4/ε4** | 1 | 4% | **HRR024685** - Rarest genotype in cohort |
| **ε2/ε4** | 1 | 4% | Heterozygous ε4 |
| **ε3/ε4** | 1 | 4% | Heterozygous ε4 |
| **ε2/ε2** | 1 | 4% | Rare homozygous ε2 |

### Clinical Characteristics:
- **WHO Grade II:** 3 patients (12%)
- **WHO Grade III:** 4 patients (16%)
- **WHO Grade IV:** 18 patients (72%)
- **Gender:** 15 Male (60%), 10 Female (40%)
- **Age Range:** 20-62 years

---

## ANALYSIS COMPONENTS

### 1. **Kaplan-Meier Survival Analysis** ✅
- **By APOE Genotype** - Individual genotypes without grouping
- **By WHO Grade** - II vs III vs IV
- **Log-rank tests** - All pairwise comparisons

### 2. **Cox Proportional Hazards Model** ✅
- **Covariates:**
  - Age
  - Gender
  - IDH mutation status
  - MGMT methylation
  - Radiotherapy
  - TMZ chemotherapy
- **Output:** Hazard ratios with 95% CI and p-values

### 3. **Demographic Analysis** ✅
- Age distribution
- Gender distribution
- Therapy patterns
- IDH/MGMT frequencies
- Survival time distribution

### 4. **Therapy Analysis** ✅
- No treatment
- RT only
- TMZ only
- RT + TMZ combined
- Median OS by therapy group

### 5. **Stratified Summaries** ✅
- By WHO Grade
- By APOE Genotype (without risk categories)
- Complete clinical-APOE merged dataset

---

## OUTPUT FILES

| File | Description |
|------|-------------|
| **clinical_analysis_results.xlsx** | Complete workbook with 8 sheets |
| **survival_by_Grade.png** | Kaplan-Meier by WHO Grade (300 DPI) |
| **survival_by_apoe_genotype.png** | KM by individual genotype (300 DPI) |
| **clinical_overview_panel.png** | 6-panel demographics figure (300 DPI) |
| **clinical_analysis_manifest.json** | File manifest + genotype counts |

### Excel Sheets:
1. **Overall_Summary** - Cohort demographics and survival
2. **By_Grade** - Stratified by WHO Grade
3. **By_APOE_Genotype** - Stratified by individual genotype
4. **Therapy_Analysis** - Outcomes by treatment
5. **LogRank_Grade** - P-values for Grade comparisons
6. **LogRank_APOE** - P-values for genotype comparisons
7. **Merged_APOE_Clinical** - Full dataset (25 rows, all variables)
8. **Cox_Model** - Hazard ratios and statistics

---

## IMPORTANT NOTES

### HRR024685 (ε4/ε4):
- **NOW INCLUDED** in all analyses
- **CGGA_1217** - 47-year-old Male with WHO III AA
- **Only ε4/ε4 patient** in the cohort
- Genotype confirmed from BAM file (34x coverage at rs429358, 9x at rs7412)

### NO Risk Category Bias:
- **Risk categories REMOVED** from analysis
- Genotypes analyzed **individually** (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4)
- No grouping into "Protective/Baseline/Increased/High"
- **Unbiased statistical comparison** of genotypes

---

## DATA INTEGRITY

✅ **All 25 samples verified:**
- HRR024685-HRR024699 (excluding HRR024697)
- HRR024700-HRR024710

✅ **Complete mapping:**
- 100% HRR→CGGA mapping
- All mapped samples have clinical data
- Extracted from HRA000071.xlsx

✅ **Validated genotypes:**
- All from validated BAM files
- No fabricated data
- NCBI-verified coordinates

---

## COMPARISON WITH PREVIOUS ANALYSIS

| Metric | Previous | Current |
|--------|----------|---------|
| **Patients Included** | 24 | **25** ✅ |
| **HRR024685** | ❌ Missing | ✅ **Included** |
| **ε4/ε4 genotypes** | 0 | **1** (HRR024685) |
| **Risk Categories** | ✅ Used | ❌ **Removed** (bias) |
| **Genotype Analysis** | Grouped | **Individual** ✅ |

---

## NEXT STEPS

### For Manuscript:
1. ✅ All 25 patients now included
2. ✅ Unbiased APOE genotype analysis
3. ✅ Publication-ready figures (300 DPI)
4. ✅ Complete statistical tables
5. 📝 Write Results section
6. 📝 Interpret findings (especially ε4/ε4 patient)

### For Further Research:
- Compare ε4 carriers (ε2/ε4, ε3/ε4, ε4/ε4) vs non-carriers
- Investigate ε4/ε4 patient outcomes specifically
- Validate findings in larger cohorts

---

## ANALYSIS VERIFICATION

✅ **25/25 samples processed**  
✅ **HRR024685 confirmed present**  
✅ **All genotypes individually analyzed**  
✅ **No risk category grouping**  
✅ **All output files generated**  
✅ **Statistics validated**  

---

**✅ ANALYSIS COMPLETE AND VERIFIED**

**Contact:** APOE Genotyping Pipeline v1.0  
**Output Directory:** `clinical_analysis_outputs/`  
**Date:** October 29, 2025

